Slender Medical Ultrasound Without Limits

2 Confidential Introduction  Founded Headquarters – Herzliya, Israel  Technology: Non-invasive excess-fat removal using high intensity focused ultrasound  Market: Aesthetic market, clinics of plastic surgeons and dermatologists, medical SPAs  Large market opportunity: $8 B  Launch in 2010  Exciting near term exit prospect  Experienced, multi-disciplinary team  Strong IP  Developmental phase: Preclinical phase

3 Confidential Chin Liposuction Before After Results obtained by standard liposuction

4 Confidential Large Market Opportunity  Up to 80% of all women over the age of 20 struggle with excess fat  495,000 potential professional users WW (source: M. Moretti, Medical Insights Inc.)  45,000 dermatologists, plastic surgeons  (150,000 SPA, paramedical)  300,000 other physician specialties (15%)  Estimated end user price $90,000  Total market opportunity: $8 B (Only for the capital part. Consumables will create additional revenue)

5 Confidential Surgical vs. Nonsurgical Procedures Liposuction total expenditure:$1.4 B A American Society for Aesthetic Plastic Surgery, 2007

6 Confidential Product  Ultrasonic elements applied to the treated area  Focused ultrasound for breaking down adipose tissue  Through transmission ultrasound for monitoring the treatment process  Treatment and monitoring are performed in a closed loop  Ultrasonic transmission is performed parallel to the skin.  Optional several sizes of hand held probe  Short time to market (Launch in 2010)

7 Confidential Technology Benefits  Skin parallel transmission. Safer  avoiding bone pain  preventing transmission of acoustic energy to internal organs  Ability to treat organs that cannot be treated by the competitors (chin and arms)  Temperature feedback. Higher efficacy & Safer  Tissue (muscle/fat) differentiation. Safer  Several probe designs allowing treatment of both large and small areas such as chin and arms. More treatment opportunities for the physician

8 Confidential Team  Dr. Liat Tsoref, Founder and CEO EarlySense – Director of BD; Sunlight Medical (bone assessment ultrasound)- VP R&D; PhD in Physics, TAU  Prof. Haim Azhari, Founder and CTA Researcher in the Technion  Mr. Gregory Krasnov, R&D Eng. MSc, Ultrasound specialist, JetGuide Ltd., Technion  Yossi Gross, Founder and Consultant Serial entrepreneur (VisionCare, BioControl, TransPharma, BrainsGate, Beta-O 2 etc.)  Dr. Amiram Borenstein, Consultant MD, MSc, Plastic and Aesthetic Surgeon

9 Confidential Objective - Investment  Investment to date: Rainbow Medical Ltd: $ 1,000,000  "A" Round Target $ 2M  A-Round UOP  Clinical study, phase I and II  Development of a beta prototype  CE clearance

10 Confidential Summary  Body shaping is a promising market with very high growth potential  Short time to market – LAUNCH in 2010  Multidisciplinary team with many years of experience in the field of ultrasound  A unique and proprietary technology  The combination of focused ultrasound treatment and monitoring abilities will turn Slender Medical into a leader in the body shaping market